Title: Clinical features and outcomes of COVID-19 patients with
benign prostatic hyperplasia in aging male: A retrospective study of 18
cases
Aim : A worldwide pandemic of coronavirus disease 2019
(COVID-19) which emerged in China
in December 2019 affects the world very seriously. We aimed to evaluate
the benign prostatic hyperplasia (BPH) patients who were admitted and
treated to our hospital due to COVID-19.
Methods : Between March 18, 2020 and April 5, 2020, 18 patients
admitted with COVID-19 who has BPH and are using medication for this
were included in the study and analyzed retrospectively. Diagnosis was
confirmed by COVID-19 nucleic acid test by sampling sputum or
nasopharyngeal swab. Standard COVID-19 treatment protocol determined by
our Ministry of Health was applied to all patients according to their
risk groups. Epidemiological, clinical, radiological features,
additional diseases, laboratory tests, complications and outcome data of
all patients were recorded.
Results : Mean age of patients was 59.6 (range: 56-73). As the
mode of transmission, 10 (55.5%) of patients were infected in hospital,
5 (27.7%) patients had a relative with COVID-19 and 3 (16,6%) was
unknown. During follow-up, 2 (11.1%) patients were transferred to
intensive care unit (ICU). One of these patients dramatically progressed
and died. Patients who survived and were not transferred to ICU had
lesser comorbidities and were relatively young. Mean duration of
hospitalization was 14.2 days (range 12-19).
Conclusion : We think that COVID-19 patients with BPH had a low
mortality rate and did not have a poor prognosis in this patient group.
It is crucial to take comprehensive preventive measures to control
COVID-19 transmission via hospital route.
Keywords: Benign prostatic hyperplasia; COVID-19; Nosocomial
infection; Outcome; Pandemic
What’s known
• Risk management is essential for the management of
acute coronary syndrome.
• The GRACE and CRUSADE scores are amongst the most
widely used tools to estimate risk of death or major bleeding.
What’s new
• The GRACE score has good prediction capability for
in‐hospital death in patients with acute coronary syn‐
drome, and is superior to CRUSADE.
• ItisalsobetterthanCRUSADEtopredictmajorbleed‐
ing, although the latter score was specifically developed
for bleeding